(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 and June 3 was host to the Poster Session: Genitourinary Cancer - Kidney and ...

The initial insertion of a suprapubic catheter (SPC), a procedure referred to as a suprapubic cystostomy, can be performed under local or general anesthesia with a trocar system, using cystoscopic or ...

ASCO 2025, Prostate Cancer, androgen deprivation therapy (ADT), HSV-tk gene, Prodrug, intraprostatic injections of CAN-2409, CAN-2409, CAN-2409 plus Prodrug, External Beam Radiation for Newly ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a kidney and bladder cancers poster ...

(UroToday.com) The 2025 European Association of Urology (EAU) Annual Congress held in Madrid, Spain was host to a plenary session on organ-sparing paradigms in kidney and bladder cancer. Dr. Peter ...

Usually, the bladder can hold urine for 4 to 5 hours, then you feel the urge to pee (urinate) and you should be able to walk to the bathroom. But some people will have an overactive bladder and feel a ...

Sequential intravesical gemcitabine and docetaxel (Gem/Doce) has been a notable advancement in the treatment of non-muscle invasive bladder cancer (NMIBC) since Michael O’Donnell developed this ...

ASCO 2025, Clear Cell Renal Cell Carcinoma (ccRCC), tumor necrosis factor (TNF), ADI-270, Armored Allogeneic Anti-CD70, Chimeric Antigen Receptor γδ, T Cell Therapy.

(UroToday.com) The 2025 ASCO annual meeting featured a kidney cancer rapid oral abstract session and a presentation by Dr. James Geller discussing results of AREN1721, a randomized phase 2 trial of ...

(UroToday.com) The 2025 ASCO annual meeting featured a prostate cancer trials in progress session and a presentation by Dr. Scott T. Tagawa discussing ProstACT Global, a phase 3 study of 177 ...

(UroToday.com) The 2024 ESMO annual meeting included a session on urothelial carcinoma, featuring a presentation by Dr. Alexandra Drakaki, discussing ctDNA clearance with neoadjuvant durvalumab + ...

The IMPACT-RCC study 7 evaluated visualization of clear cell RCC lesions in 42 patients with metastatic disease (n = 449 lesions). Patients in this study had a lesion size cutoff of 1 cm (lymph nodes ...